Experimental drug for managing aortic valve stenosis shows promise

The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.

Originally developed by Sanofi and granted to The Mayo Clinic to advance, ataciguat has demonstrated in early- and mid-stage trials the ability to reduce aortic valve calcification progression in patients with moderate aortic valve stenosis. Aortic valve stenosis involves the narrowing of the aortic valve through the deposition of calcium, forcing the heart to work harder to pump blood throughout the body. The condition can only be monitored until it is severe enough to warrant valve replacement surgery. As of 2024, aortic valve stenosis affects over 1.5 million Americans, with millions more around the world.

In the most recent trial, patients demonstrated an almost 70% reduction in calcification progression at the 6-month mark when compared to a placebo. Those receiving ataciguat also demonstrated better heart muscle function maintenance, though it is important to note the trial had a patient population of only 23 patients. A critical aspect of the studies demonstrated that though ataciguat slowed valve calcification, it did not negatively impact bone formation or density.

Subsequent trials will determine ataciguat’s long-term effectiveness, as well as safety profiles in phase III trials. The Mayo Clinic is also making efforts to find an industry partner to launch these pivotal trials, as well as navigating regulatory approval. Jordan Miller, Director of the Cardiovascular Disease and Aging Laboratory at Mayo Clinic, commented “This research represents a significant advancement in the treatment of aortic valve stenosis. Ataciguat has the potential to substantially delay or even prevent the need for valve replacement surgery, significantly improving the lives of millions.”

Sources:

Health Rounds: Experimental drug delays heart valve disease progression, and potentially surgery [Accessed February 28, 2025] https://www.reuters.com/business/healthcare-pharmaceuticals/health-rounds-experimental-drug-delays-heart-valve-disease-progression-2025-02-27/

New drug may reduce need for aortic valve surgeries by slowing disease progression [Accessed February 28, 2025] https://newsnetwork.mayoclinic.org/discussion/new-drug-may-reduce-need-for-aortic-valve-surgeries-by-slowing-disease-progression/